By PPN News Staff
The FDA granted accelerated approval to alpelisib (Vijoice, Novartis) for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) who require systemic therapy.
APRIL 6, 2022